Association of genetic polymorphisms in the DNA repair gene XRCC1 and XPD with risk of prostate cancer
10.3760/cma.j.issn.1000-6702.2009.12.018
- VernacularTitle:X线交错互补修复基因1和核苷酸剪切修复基因多态性与前列腺癌发病风险的相关性
- Author:
Jie LIU
;
Bao SONG
;
Hong WANG
;
Jun TIAN
;
Zhen CHEN
;
Huan SHI
;
Zhehai WANG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
DNA repair gene;
Polymorphism;
single nucleotide
- From:
Chinese Journal of Urology
2009;30(12):834-837
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between DNA repair gene XRCC1 and XPD polymorphisms and individual susceptibility to prostate cancer. Methods PCR-restriction fragment length polymorphism assay was used to analyze the XRCC1 (C26304T and G28152A) and XPD A35931C polymorphisms in 358 prostate cancer patients and 312 healthy controls. Unconditional logistic regression analysis was performed to calculate odd ratio (OR) and 95% confidence interval (CD for estimating the correlation between different genotypes and prostate cancer risks. Results Forty-seven(13.1%) cases present XRCC1 28152AA genotype in prostate cancer group, while 24 cases in the control group (7. 1%), individuals with this genotype had a significantly increased risk for prostate cancer (OR 1. 924, 95%CI=1.126 - 3. 288, P=0. 017). There was no significant difference between two groups at XRCC1 C26304T and XPD A35931C sites. Combined analysis of the three sites polymorphisms showed that individuals with XRCC1 28152 AA and XPD 35931AC+CC genotype had a higher risk of prostate cancer than those with three wild genotypes (OR = 3. 087,95%CI 1. 081 - 8.813;OR = 3. 376,95%CI 1.067-10.683;OR 3. 216,95%CI=1. 439-7.188,P = 0. 004). Analysis stratified by age of onset, PSA, Gleason score and T stage revealed that XRCC1 28152AA and XPD 35931 AC+CC high-risk genotype was especially associated with early age at onset of prostate cancer (P<0. 05). Conclusions The XRCC1 and XPD genotypes may be contributed to the risk of developing prostate cancer, particularly for younger patients.
